Sugammadex dosing based on ideal or actual body weight in underweight patients.

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1031230452

Enrollment

Registered

2023-11-19

Start date

2023-11-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients undergoing general anesthesia

Interventions

Sugammadex will be administered in two doses: a real-weight group and an ideal-weight group.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: BMI below 18.5 ASA-PS= 1-3

Exclusion criteria

Exclusion criteria: ppatient who is allergic to muscle relaxants patient who has neuromuscular diseases patient who has moderate to severe liver function failure Patients with hypoalbuminemia Patients taking medications that affect the muscle relaxant effect Patients who are deemed inappropriate as research subjects by the principal investigator

Design outcomes

Primary

Measure	Time frame
Time from sugammadex administration to TOFR=90%.	—

Contacts

Public ContactHanae Sato

Nihon University School of Medicin, Department of Anesthesiology

nakamura.hanae@nihon-u.ac.jp+81-3-3972-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026